Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonmyeloablative stem cell transplantation for lymphoma.

Issa F Khouri1, Richard E Champlin

  • 1Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Seminars in Oncology
|February 19, 2004
PubMed
Summary

Nonmyeloablative allogeneic stem cell transplantation offers a less toxic approach for non-Hodgkin's lymphoma (NHL). This strategy leverages graft-versus-lymphoma effects, confirming its potential for NHL treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.

American journal of hematology·2024
Same author

Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis.

Bone marrow transplantation·2024
Same author

Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.

Bone marrow transplantation·2023
Same author

<i>Bacteroides ovatus</i> alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease.

Research square·2023
Same author

Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation.

Cancer·2023
Same author

Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS.

American journal of hematology·2023

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • High-dose chemotherapy with allogeneic stem cell transplantation is a curative option for non-Hodgkin's lymphoma (NHL).
  • Treatment-related mortality often exceeds 40%, limiting its application, especially in older patients or those with comorbidities.
  • Graft-versus-malignancy effects show promise against lymphoid malignancies.

Purpose of the Study:

  • To evaluate a strategy using nonmyeloablative conditioning regimens for allogeneic transplantation in NHL.
  • To harness graft-versus-lymphoma (GVL) effects as the primary therapeutic mechanism.
  • To reduce treatment-related mortality associated with conventional high-dose therapy.

Main Methods:

  • Utilized fludarabine-based preparative regimens with optional high-dose rituximab.

Related Experiment Videos

  • Administered graft-versus-host disease (GVHD) prophylaxis for six months.
  • Reserved donor lymphocyte infusion (DLI) for progressive or nonresponding disease.

    • Main Results:

    • Confirmed the potential of nonmyeloablative transplantation for NHL.
    • Demonstrated feasibility of donor cell engraftment with reduced toxicity.
    • Exploited GVL effects as a key therapeutic component.

    Conclusions:

    • Nonmyeloablative allogeneic transplantation is a viable and less toxic alternative for NHL.
    • This approach effectively utilizes GVL effects for disease control.
    • Further confirms the therapeutic potential of nonmyeloablative strategies in lymphoid malignancies.